Skip to content
Thaler
NEPHNephros Inc·Earnings

Q3 2026

Released Nov 5, 2026, after the close

10-Q filed Nov 5, 2026, 36 days after period end · 0001493152-26-050218

Q3 2026 · 10-Q
Revenue$5.62M+18.0% vs Q3 2025−6.6% vs Q2 2026
Net Income$512.00K+51.9% vs Q3 2025−57.2% vs Q2 2026
EPS Diluted$0.05+66.7% vs Q3 2025−54.5% vs Q2 2026
Gross Profit$3,286,000+12.7%
Operating Income$501,000+59.6%
Operating Cash Flowderived-$150,000N/M
Margins · derived
Gross margin58.4%−2.7 pt vs Q3 2025
Operating margin8.9%+2.3 pt vs Q3 2025
Net margin9.1%+2.0 pt vs Q3 2025

What the release said

Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2026.

Net revenue for the three months ended September 30, 2026 increased 18% to $5.6 million, compared with $4.8 million in the same period of 2025.23

Net income for the third quarter of 2026 was $0.5 million, compared with $0.3 million in 2025, and Adjusted EBITDA was approximately $0.6 million.245

For the nine months ended September 30, 2026, net revenue was $16.9 million, up 20% from $14.1 million, and net income was $1.8 million compared with $1.1 million.67

Gross margin for the third quarter of 2026 was 58% compared with 61% a year earlier, while the nine-month period included an IEEPA tariff refund of approximately $0.6 million recorded as a reduction of cost of goods sold.89

As of September 30, 2026, Nephros had cash and cash equivalents of approximately $4.5 million, compared to $5.4 million as of December 31, 2025, and remains debt free.10

Net revenue, three months ended September 30, 2026
$5.6 million Compared with $4.8 million in the three months ended September 30, 2025, an increase of 18%3
Net revenue, nine months ended September 30, 2026
$16.9 million Compared with $14.1 million in the nine months ended September 30, 2025, an increase of 20%6
Net income, three months ended September 30, 2026
$0.5 million Compared with $0.3 million in the same period of 20254
Adjusted EBITDA, three months ended September 30, 2026
$0.6 million Compared with approximately $0.4 million in the third quarter of 20255
Gross margin, three months ended September 30, 2026
58% Compared with 61% in the third quarter of 20258
Cash and cash equivalents, September 30, 2026
$4.5 million Compared with $5.4 million as of December 31, 202510
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$5.62M$4.76M$3.52M$3.74M
Net Income$512.00K$337.00K$183.00K-$182.00K
EPS Diluted$0.05$0.03$0.02-$0.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR